Potential biomarkers for lung adenocarcinoma identified by integrative transcriptomics analysis

Kasavi, Ceyda

doi:10.38042/biotechstudies.932937

Cited by 1 publication

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FHL2 was identified initially as a biomarker of lung adenocarcinoma and has been confirmed to function as an oncoprotein in human LC. 17,18 However, until now, there is still no report that revealed the detailed role of FHL2 in NSCLC. In this research, we preliminarily explored the efficacies of FHL2 on NSCLC both in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 99%

“…Besides, Al‐Nomani et al found that there was a close association between lymphatic metastasis and enhanced FHL2 expression in sporadic colorectal cancer 16 . Importantly, FHL2 wasdescribed previously as a biomarker of lung adenocarcinoma and was recorded to be working as an invasion‐promoting gene facilitating the progression and metastasis of human LC 17,18 . Nevertheless, the effects of FHL2 on NSCLC still remains under investigated to date.…”

Section: Introductionmentioning

confidence: 99%

“…16 Importantly, FHL2 was described previously as a biomarker of lung adenocarcinoma and was recorded to be working as an invasion-promoting gene facilitating the progression and metastasis of human LC. 17,18 Nevertheless, the effects of FHL2 on NSCLC still remains under investigated to date.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High level of FHL2 exacerbates the outcome of non‐small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells

Zhang

et al. 2022

Int J Experimental Path

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is a malignant tumour with high mortality.FHL2 has been identified as a biomarker of lung cancer. This research explored the effects of FHL2 expression on NSCLC. NSCLC-associated data sets were collected from the assistant for clinical bioinformatics and TCGA databases respectively. The association between FHL2 and clinical characteristics, the prognostic significance of FHL2 and the influences of various variables on NSCLC were determined by Pearson's chi-squared test, the Kaplan-Meier curve and the Cox regression model respectively. FHL2 level was altered by cell transfection and was measured by qRT-PCR. Tumour xenograft formation was completed by inoculating sh-FHL2/pcDNA-FHL2 transfected cells into BALB/c nude mice. Protein expression was assessed by western blot. Cell apoptosis, proliferation and epithelial -mesenchymal transition (EMT) characteristics were evaluated employing TUNEL, BrdU + and microscopic observation respectively. The expression of Ki67 and N-cadherin was assessed by immunohistochemistry. The results showed that FHL2 was highly expressed in NSCLC tissues. Patients with high FHL2 expression experienced lower overall survival probability. FHL2 knockdown promoted apoptosis, but inhibited EMT of A549 and NCI-H460 cells, which was verified by the increased ratios of cleaved caspase 9/caspase 9 and cleaved caspase 3/caspase 3, as well as augmented E-cadherin and reduced N-cadherin. In an in vivo assay FHL2 knockdown decreased tumour volume and weight, repressed EMT, but enhanced apoptosis. FHL2 upregulation showed the opposite effects of FHL2 knockdown. Furthermore, FHL2 upregulation facilitated cell proliferation both in in vitro and in vivo assays. These outcomes indicated that high level of FHL2 facilitated tumorigenesis, as well as the proliferation and EMT of NSCLC cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High level of FHL2 exacerbates the outcome of non‐small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells

Zhang

et al. 2022

Int J Experimental Path

View full text Add to dashboard Cite

show abstract

Potential biomarkers for lung adenocarcinoma identified by integrative transcriptomics analysis

Abstract: How to CiteKasavi, C. (2021). Potential biomarkers for lung adenocarcinoma identified by integrative transcriptomics analysis.

Cited by 1 publication

References 46 publications

High level of FHL2 exacerbates the outcome of non‐small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells

High level of FHL2 exacerbates the outcome of non‐small cell lung cancer (NSCLC) patients and the malignant phenotype in NSCLC cells

Contact Info

Product

Resources

About